

IN THE CLAIMS

14. (AMENDED) A method according to claim 12 wherein the antisense molecule comprises the nucleotide sequence:

5'-ATCTCTCCGCTTCCTTTC-3' [(<400>10)] (SEQ ID NO. 10).

- A4  
15. (AMENDED) A method according to claim 12 wherein the antisense molecule [is] has a sequence selected from the [following] group consisting of:

UCCGGAGCCAGACUU [(<400>12)] (SEQ ID NO. 12);

CACAGUUGCUGCAAG [(<400>13)] (SEQ ID NO. 13);

UCUCCGCUUCCUUUC [(<400>14)] (SEQ ID NO. 14);

AGCCCCACAGCGAG [(<400>15)] (SEQ ID NO. 15);

GCCUUGGAGAUGAGC [(<400>16)] (SEQ ID NO. 16);

UAACAGAGGUCAGCA [(<400>17)] (SEQ ID NO. 17);

GGAUCAGGGACCAGU [(<400>18)] (SEQ ID NO. 18);

CGGCAAGCUACACAG [(<400>19)] (SEQ ID NO. 19) and

GGCAGGCAGGCACAC [(<400>20)] (SEQ ID NO. 20).

16. (AMENDED) A method according to claim 15 wherein the antisense molecule [is <400>12, <400>13 or <400>14] has the sequence of SEQ ID NO. 12, SEQ ID NO. 13 or SEQ ID NO. 14.

17. (AMENDED) A method according to claim 15 wherein the antisense molecule [is <400>12] has the sequence of SEQ ID NO. 12.

18. (AMENDED) A nucleic acid molecule comprising at least about 10 nucleotides capable of hybridising to or forming a heteroduplex or otherwise interacting with a complementary form of [<400>12 to <400>20] SEQ ID NOS. 12 to 20 inclusive.

A4  
CmT

19. (AMENDED) A nucleic acid molecule comprising at least about 15 nucleotides capable of hybridising to or [form] forming a heteroduplex or otherwise interacting with a complementary form of [<400>12 to <400>14] SEQ ID NOS. 12 to 14 inclusive.

---

AS

23. (AMENDED) A method according to claim 22 wherein the nucleic acid molecule is capable of interacting with a [nucleotide] nucleic acid molecule comprising a sequence selected from [the list set forth in <400>12 to <400>14] SEQ ID NOS. 12 to 14 inclusive.

---

24. (AMENDED) A method according to claim 23 wherein the nucleic acid molecule comprises the nucleotide sequence selected from [<400>12 to <400>14] SEQ ID NOS. 12 to 14 inclusive.

---

Ab

27. (AMENDED) A composition according to claim 26 wherein the nucleic acid molecule [is] has a sequence selected from [<400>12 to <400>20] SEQ ID NOS. 12 to 20 inclusive.

---

28. (AMENDED) A composition according to claim 26 having a nucleotide sequence selected from [<400>12 to <400>14] SEQ ID NOS. 12 to 14 inclusive.

---

A7

38. (AMENDED) A method according to claim 37 wherein the antisense molecule comprises the nucleotide sequence:

5'-ATCTCTCCGCTTCCTTTC-3' [(<400>10)] SEQ ID NO. 10

39. (AMENDED) A method according to claim 37 wherein the antisense molecule [is] has a sequence selected from the [following] group consisting of:

UCCGGAGCCAGACUU [(<400>12)] (SEQ ID NO. 12);

CACAGUUGCUGCAAG [(<400>13)] (SEQ ID NO. 13);

UCUCCGCUUCCUUUC [(<400>14)] (SEQ ID NO. 14);

AGCCCCCACAGCGAG [(<400>15)] (SEQ ID NO. 15);  
GCCUUGGAGAUGAGC [(<400>16)] (SEQ ID NO. 16);  
UAACAGAGGUCAGCA [(<400>17)] (SEQ ID NO. 17);  
GGAUCAGGGACCAGU [(<400>18)] (SEQ ID NO. 18);  
CGGCAAGCUACACAG [(<400>19)] (SEQ ID NO. 19); and  
GGCAGGCAGGCACAC [(<400>20)] (SEQ ID NO. 20).

A7  
cont

40. (AMENDED) A method according to claim 39 wherein the antisense molecule [in <400>12, <400>13 or <400>14] has the sequence of SEQ ID NO. 12, SEQ ID NO. 13 or SEQ ID NO. 14.
41. (AMENDED) A method according to claim 40 wherein the antisense molecule [in <400>12] has the sequence of SEQ ID NO. 12.
-